Pathogenic variants associated with the disease have been identified in all exons of the DYSF gene, and, due to the variant-specific nature of exon skipping strategies, each exon skipping strategy would only be applicable to a subset of the dysferlinopathy patient population. The gene discussed is DYSF; the disease is neuromuscular disease caused by qualitative or quantitative defects of dysferlin.